Details

Autor(en) / Beteiligte

• Rialdi, Alex
• Duffy, Mary
• Scopton, Alex P
• Fonseca, Frank
• Zhao, Julia Nanyi
• Schwarz, Megan
• Molina-Sanchez, Pedro
• Mzoughi, Slim
• Arceci, Elisa
• Abril-Fornaguera, Jordi
• Meadows, Austin
• Ruiz de Galarreta, Marina
• Torre, Denis
• Reyes, Kyna
• Lim, Yan Ting
• Rosemann, Felix
• Khan, Zaigham M
• Mohammed, Kevin
• Wang, Xuedi
• Yu, Xufen
• Lakshmanan, Manikandan
• Rajarethinam, Ravisankar
• Tan, Soo Yong
• Jin, Jian
• Villanueva, Augusto
• Michailidis, Eleftherios
• De Jong, Ype P
• Rice, Charles M
• Marazzi, Ivan
• Hasson, Dan
• Llovet, Josep M
• Sobota, Radoslaw M
• Lujambio, Amaia
• Guccione, Ernesto
• Dar, Arvin C

Titel

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma

Ist Teil von

• Nature cancer, 2023-08, Vol.4 (8), p.1157-1175

Ort / Verlag

England

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. β-Catenin (CTNNB1)-mutated HCC represents 30% of cases of the disease with no precision therapeutics available. Using chemical libraries derived from clinical multi-kinase inhibitor (KI) scaffolds, we screened HCC organoids to identify WNTinib, a KI with exquisite selectivity in CTNNB1-mutated human and murine models, including patient samples. Multiomic and target engagement analyses, combined with rescue experiments and in vitro and in vivo efficacy studies, revealed that WNTinib is superior to clinical KIs and inhibits KIT/mitogen-activated protein kinase (MAPK) signaling at multiple nodes. Moreover, we demonstrate that reduced engagement on BRAF and p38α kinases by WNTinib relative to several multi-KIs is necessary to avoid compensatory feedback signaling-providing a durable and selective transcriptional repression of mutant β-catenin/Wnt targets through nuclear translocation of the EZH2 transcriptional repressor. Our studies uncover a previously unknown mechanism to harness the KIT/MAPK/EZH2 pathway to potently and selectively antagonize CTNNB1-mutant HCC with an unprecedented wide therapeutic index.